Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sanofi: Lyxumia Plus Insulin Shows Promise in PIII Study
June 27, 2011
- Korosho Council Approves Draft Report on Measures against Rheumatism, Allergy
June 27, 2011
- JPMA Suspends MSD from Membership for Violations of Promotion Code
June 27, 2011
- Novoseven Approved for Glanzmann Thrombasthenia
June 27, 2011
- Zeria's Z-338 Effective for 3 Major Meal-related Symptoms
June 27, 2011
- Doctors Appreciate Companies That Supply Information in Emergencies
June 27, 2011
- HeW CO-OP JAPAN Aims to Jointly Purchase ¥3 Bil. Worth of Drugs in FY2011
June 27, 2011
- Bayer HealthCare Applies for VEGF Trap-Eye in Europe
June 27, 2011
- Radioactive Anticancer Agent Significantly Extends OS in PIII Study: Bayer HealthCare
June 27, 2011
- Mediceo Aims to Attract More Customers in Nagoya Area through New ALC
June 27, 2011
- Sanofi to Apply for Zaltrap for mCRC in Europe, US in 2011
June 27, 2011
- Terumo to Expand into Infusion Products Market in China
June 27, 2011
- MSD, Taiho Announce Marketing Tie-up for CTCL Treatment Vorinostat
June 27, 2011
- More Companies Collaborating in Development of Combination Therapies Using New Drugs
June 27, 2011
- Further Analysis Confirms Usefulness of SGN-36: Takeda
June 27, 2011
- Korosho to Invite Requests for Development of Unapproved Drugs/Applications in August
June 27, 2011
- Council Approves Basic Policy for Promotion of Medical Innovation
June 27, 2011
- Roche Confirms Efficacy of Actemra Monotherapy
June 27, 2011
- GenomIdea Ties Up with TSD Japan for Licensing HVJ-E
June 27, 2011
- Korosho to Create ICH GCP-Compliant “Clinical Research Core Hospitals”
June 27, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…